Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
No Endocrine Therapy in Small HR+/HER2- Low Risk Luminal A Early Breast Cancer
NCT07661927Phase 2Recruiting
- Sponsor
- Unicancer
- Start
- Jul 2026
- Primary completion
- Jul 2033
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in breast cancer, sponsored by Unicancer. Primary endpoint: Relapse-free interval at 5 years. Started Jul 2026; status: recruiting.
02
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07661927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07661927.